PVI
PTCT icon

Pura Vida Investments’s PTC Therapeutics PTCT Stock Holding History

Pura Vida Investments’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-84,338
Closed -$3.17M – 119
2019
Q1 		$3.17M Buy
+84,338
New +$2.83M 0.45% 64

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Pura Vida Investments's PTCT Position: Q2 2019 in Review

Pura Vida Investments sold out of PTC Therapeutics (PTCT) in Q2 2019, closing a stake of 84,338 shares — an estimated $3.17M sold.

Pura Vida Investments first reported a position in PTCT in Q1 2019 and held it in 1 quarter. The position peaked at $3.17M in Q1 2019. 176 funds tracked by Wall St. Rank hold PTCT as of Q2 2019.

  • Pura Vida Investments reported no remaining PTC Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pura Vida Investments sold 84,338 PTC Therapeutics shares in Q2 2019, an estimated $3.17M.
  • Pura Vida Investments first reported a position in PTC Therapeutics in Q1 2019 and held it in 1 quarter.
  • Pura Vida Investments's PTC Therapeutics position peaked at $3.17M in Q1 2019.
  • 176 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2019.

Based on Pura Vida Investments's 13F filing for Q2 2019, filed 14 Aug 2019.